Humalog (Lispro) is an insulin analog produced by recombinant DNA technology, it is chemically identical to human insulin except that the location of 2 amino acids - Lysine and Proline have been changed. This gives an insulin which has a much more rapid onset of action and shorter duration of action than Regular Insulin. It is manufactured by Eli Lilly & Co.
Regular Insulin has an onset of action about 1 hour after injection and the effect peaks in 4 hours and lasts 6 hours.
Humalog (Lispro) has an onset of action about 30 minutes after injection and a peak effect at 1 hour with essentially
no effect 2 hours after injection.
Blood glucose starts to rise less than 30 minutes after a meal, thus Humalog is able to deal with this glucose rise earlier than Regular Insulin. As expected, there is less hyperglycemia 1 or 2 hours after a meal than there is using Regular Insulin and there is less hypoglycemia 3 to 4 hours after a meal than with Regular Insulin. In other words the action of Humalog is closer to the action of food and it is therefore an effective insulin to take with meals.
Humalog may be used in Intensive Insulin Treatment Routines in which Insulin is given with each meal and it may also be used in an insulin pump.
It is supplied in 10 ml Vials for administration with a syringe or 3 ml cartridges for use in the Humapen supplied by Lilly Pharmaceuticals. The vials will also drop right in to the Disetronic C-Tron insulin pump.